Supplementary Figure 2 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 2999K, SAR3419 is effective against BCP-ALL xenografts in vivo over a broad dose range. Mice engrafted with ALL-4 (A) were treated with vehicle control (dotted black line), or SAR3419 at 10 mg/kg (solid red line), 7.5 mg/kg (solid green line), 5 mg/kg (solid blue line), 2.5 mg/kg (solid orange line) or with the unconjugated MAb huB4 (gray dotted line) while mice engrafted with ALL-19 (B) were treated with vehicle control (dotted black line), or SAR3419 at 10 mg/kg (solid red line) and at 1.0 mg/kg (solid blue line). Response to treatment was monitored by weekly enumeration of the proportion of %huCD45+ cells in the PB of individual mice (left panels), and Kaplan-Meier analysis of EFS (right panels). Gray arrows indicate treatment time points.
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362395825